<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Novavax Inc (NASDAQ: NVAX) is trading lower Friday following reports suggesting that the company could have trouble meeting its 2022 vaccine targets. Novavax’s ability to obtain U.S. Food and Drug Administration approval and to produce enough doses in manufacturing sites other than India’s Serum Institute remains in question, according to a Politico report.
...read full article on Benzinga
